Epidemiology of Gonococcal Arthritis (EpGAr)
Launched by UNIVERSITY HOSPITAL, BREST · Mar 20, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
The Epidemiology of Gonococcal Arthritis (EpGAr) trial is designed to study a specific type of arthritis caused by a bacterial infection called Neisseria gonorrhoeae, which is often associated with gonorrhea. Over the past ten years, researchers at Brest and Rennes university hospitals have been looking into how common this infection is and what factors might put someone at risk for developing arthritis from it. They’re also interested in understanding the different types of bacteria involved and whether there are any common traits among them that could explain why some individuals get sick.
To be eligible for this study, participants need to have a joint sample that tests positive for Neisseria gonorrhoeae taken between 2014 and 2024. Unfortunately, those with a negative test result or who do not wish to participate cannot join. If you qualify and choose to take part, you can expect to contribute data that will help researchers better understand this infection and its effects. The insights gained from this study could ultimately improve treatment and prevention strategies for gonococcal arthritis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a Neisseria gonorrhoeae-positive joint sample (from an enrichment vial or a native sample) between 2014 and 2024.
- Exclusion Criteria:
- • Patients with Neisseria gonorrhoeae-negative joint sample (from enrichment vial or native sample).
- • Patients who have expressed opposition to inclusion in the study.
- • Patients under legal protection (guardianship, curatorship, etc.).
About University Hospital, Brest
The University Hospital of Brest is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. With a strong emphasis on interdisciplinary collaboration, the hospital serves as a hub for cutting-edge clinical trials aimed at improving treatment outcomes across various medical specialties. Leveraging its robust academic affiliations and state-of-the-art facilities, the University Hospital of Brest is committed to fostering scientific discovery and enhancing the quality of life for patients through evidence-based practices and pioneering research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brest, , France
Rennes, , France
Patients applied
Trial Officials
Geneviève HERY-ARNAUD
Principal Investigator
CHU de Brest
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported